Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
Portfolio Pulse from
Helius Medical Technologies, Inc. announced positive long-term results from their PoNS Therapy on gait improvement in Multiple Sclerosis patients. The PoNSTEP study showed statistically significant improvements in the Dynamic Gait Index among participants.
January 22, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Helius Medical Technologies announced significant long-term benefits of their PoNS Therapy for Multiple Sclerosis patients, showing improvements in gait. This could positively impact the company's stock as it demonstrates the therapy's effectiveness.
The announcement of positive clinical evidence for PoNS Therapy in improving gait in MS patients is likely to boost investor confidence in Helius Medical Technologies. The statistically significant results from the PoNSTEP study highlight the therapy's effectiveness, which could lead to increased adoption and sales, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100